Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000, with Q4 revenue at $49.9 million, representing an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss for Q4 was $63 million, including a $25.8 million non-cash impairment charge, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% when excluding the prior year's CleanCap revenue [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809 from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company were dismissed, reflecting positive progress in resolving legal matters [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [34][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing customer engagement [43] Question: Expectations for 2026 and potential challenges - Management remains optimistic for Q1 and the year, with no significant negative comps expected, and strong customer spending observed [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94]

Maravai LifeSciences (NasdaqGS:MRVI) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsBernd Brust - CEOChanfeng Zhao - SVP and Chief Scientific OfficerDebra Hart - Head of Investor RelationsDoug Schenkel - Managing DirectorRajesh Asarpota - EVP and CFOConference Call ParticipantsJosh Heinen - Research AnalystJustin Bowers - Equity Research AnalystMatt Hewitt - Senior Research AnalystMatt Larew - Research AnalystMatt Stanton - VP and Equity Research AnalystMatthew Parisi - Research Ana ...

Maravai LifeSciences (NasdaqGS:MRVI) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Speaker8Ladies and gentlemen, thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time today, please press star 0 and a member of our team will be happy to help you. Again, ladies and gentlemen, thank you for your continued patience. Your meeting will begin shortly. Again, if you do need assistance at any time today, please press star 0 and a member of our team will be h ...

NASDAQ: MRVI Q4 and Year-end 2025 Financial Results February 25, 2026 Agenda | 01 | Welcome | Deb Hart, Head of Investor Relations | | --- | --- | --- | | 02 | Business Highlights | Bernd Brust, Chief Executive Officer | | 03 | Financial Results | Raj Asarpota, Chief Financial Officer | | | & Guidance | | | 04 | Q&A Session | Bernd Brust, Chief Executive Officer | | | | Raj Asarpota, Chief Financial Officer | | | | Chanfeng Zhao, Chief Scientific Officer | ©2026 Maravai LifeSciences. This document and its c ...

Financial Performance - Q3 2025 revenue was $41.6 million[32] - Nucleic Acid Products (NAP) revenue was $25.4 million[15, 33] - Biologics Safety Testing (BST) revenue was $16.3 million[14, 33] - GAAP Net Loss was $45.1 million[38] - Adjusted EBITDA was a loss of $10.8 million[38] - Basic and Diluted EPS were both losses of $0.18, while Adjusted EPS was a loss of $0.08[40] - Cash used in operations was $15.2 million[44] Guidance and Future Outlook - The company expects to lower annualized expenses by more than $50 million[17] - The company anticipates sequential Adjusted EBITDA improvements in Q4 of more than $7 million[17] - The company expects annual revenue contribution from COVID GMP CleanCap® to be $10 million to $20 million starting in 2026[23] - 2025 revenue is expected to be approximately $185 million, and Adjusted EBITDA is expected to be a loss of approximately $35 million[51]